Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-Positive, estrogen receptor-positive primary breast cancer: Evidence from a Phase III randomised Trial. - Ellis,M.J.; Coop,A.; Singh,B. (J Clin Oncol, 2001)